Holdings announced a broad strategic collaboration with Hologen. MeiraGTx will receive $200 million in upfront cash at closing ...

Reports FY24 revenue $33.279M vs $14.017M last year. “MeiraGTx (MGTX) demonstrated excellent execution in 2024, marked by significant ...

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders. Now it’s on the cusp of its first regulatory approval. Each year ...

In other MeiraGTx news, CEO Alexandria Forbes sold 35,839 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $6.47, for ...

MeiraGTx (MGTX) stock rose 7% after publishing promising results from the first human trial using gene therapy to treat AIPL1-associated severe retinal dystrophy in children. Across all trials so ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene therapy, data that are prompting the biotech to seek accelerated approval ...

MeiraGTx is advancing its investigational gene therapy toward expedited approval in the UK after 11 children who were born blind from birth gained significant vision improvements following treatment.

Gene therapy specialist Meiragtx Holdings plc is heading for its first marketing approval following the successful treatment of 11 children with Leber amaurosis, a severe form of congenital retinal ...

MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind. As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal ...

MeiraGTx Holdings plc announced promising results from a first-in-human study published in The Lancet, involving a gene therapy treatment for children with AIPL1-associated retinal dystrophy ...

Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment. The stock was recently up 9.1% ...

(RTTNews) - MeiraGTx Holdings Plc. (MGTX), a clinical-stage genetic medicines company, on Friday announced the progress in its gene therapy program for Leber Congenital Amaurosis 4 or LCA4 ...